Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World February 28, 2013 Andrew Turley	Does chemical regulation boost innovation? According to a report from the Center for International Environmental Law, a US environmental group, tougher chemical regulation has sparked the continuous invention of safer chemicals.
The Motley Fool July 16, 2010 Stephen Mauzy	Banks: The Bigger, The Better Big banks will continue to benefit from being too big too fail.
Reason January 2005 Julian Sanchez	Data Unhealthy Regulations: Many Americans see government regulation as the only way to ensure high-quality health care and broad access to medical services.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
U.S. Banker February 2011 Alan Kline	One Senator's Plan For Cutting Red Tape It's not getting much attention, but Virginia Sen. Mark Warner's proposal for easing the regulatory burden on U.S. businesses might be one of the most intriguing ideas coming out of Washington these days.
The Motley Fool October 5, 2011 Morgan Housel	Why the Jobs Disappeared It's lack of demand, not regulation, that's causing jobs to disappear.
The Motley Fool October 12, 2009	Last Call for Questions for the White House Got ideas for better financial regulation? We can take them to the Obama Administration.
Insurance & Technology April 3, 2009 Anthony O'Donnell	Industry Reacts to Federal Insurance Regulation Bill Insurance industry associations argue the benefits or drawbacks of federal regulation, optional federal charter and the priority of addressing systemic risk over shortcomings of the existing state-based regulatory regime.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
Reason October 2007 Jonathan Rauch	Flying Blind in a Red-Tape Blizzard How George W. Bush became the regulator in chief.
Insurance & Technology July 25, 2005 Katherine Burger	A Matter of Time Federal regulation of the U.S. insurance industry is coming - maybe not this year, or even for a few years, but it is inevitable.
Wall Street & Technology February 25, 2005	Regulators in the Driver's Seat Regulation is here to stay and remains the No. 1 driver for IT organizations within securities and investments businesses for 2005, says recently released research by TowerGroup.
The Motley Fool October 20, 2008 Brian Orelli	Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma.
The Motley Fool November 14, 2005 Richard Gibbons	Unstoppable Stocks, Phenomenal Returns Identify superior investments by recognizing extraordinary competitive advantages and then purchase them for much less than they're worth.
Registered Rep. January 1, 2006	60 Seconds With...Grace Vogel An interview with the executive vice president of Member Firm Regulation for New York Stock Exchange Regulation about regulatory duplication and the NYSE's enforcement record.
Insurance & Technology February 19, 2009 Anthony O'Donnell	Federal Insurance Regulatory Proposal Draws Fire, Support Opponents of the National Insurance Consumer Protection and Regulatory Modernization Act (NICPRMA) call the bill an attempt to shoehorn optional federal charter into government regulatory activity meant to address systemic risk within financial services.
Search Engine Watch July 30, 2010 Frank Watson	Impact of Legal U.S. Online Gambling on Search and the Web The search industry may profit from increased PPC advertising cash. However, forum and blog comment spam will no doubt increase and endless new content will hit the web, taxing search engine crawlers.
Bank Director 3rd Quarter 2009 John Berlau	Overregulation Plan Won't Fix Financial Crisis Initial reports indicate that these early hopes of a more accountable regulatory structure from the Obama administration have been dashed.
The Motley Fool April 14, 2008 Anand Chokkavelu	Why Paulson's Plan Works Saluting the Secretary of the Treasury's proposed overhaul of financial institution regulations.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
The Motley Fool October 6, 2009 Jennifer Schonberger	This Is How We Should Fix the Financial System Economist Simon Johnson says a decision about regulating derivatives was the defining event.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
Chemistry World May 23, 2012 Andy Extance	Drug watchdogs mark out global territory The US Food and Drug Administration has published plans to ensure that American citizens continue to enjoy access to safe drugs, even as the regulatory pressures of globalization grow.
Chemistry World April 6, 2011 Andrew Turley	Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'.
Registered Rep. November 1, 2006 John Churchill	Insider Trading Up in 2006 NYSE Regulation says it expects to refer 140 potential insider-trading cases to the SEC in 2006.
CFO January 1, 2002 Stephen Barr	A Graham of Prevention The Bush Administration has changed its tactics for ridding business of regulations deemed undesirable. Meet the man who's now in charge.
The Motley Fool July 23, 2010 Morgan Housel	Straight Talk From a Bank Lobbyist An insider sounds off on financial reform.
Entrepreneur April 2004 Mike Hogan	Do We Have Lift-Off? VoIP is a bottle rocket, but red tape could ground it.
The Motley Fool October 19, 2009 Brian Orelli	Foolish Forecast: A Last Look at "Mini" Pfizer In advance of Pfizer's last earnings report before their acquisition of Wyeth, analysts expect a drop in sales and a bigger bottom line decrease.
Insurance & Technology November 14, 2007 Kim Dorgan	Life Insurance Industry Would Benefit From Optional Federal Charter The future of insurance regulation remains one of the most critical issues facing the life insurance industry.
Investment Advisor May 1, 2011 Bob Clark	The Polar Bears Thawing out our modern black and white thinking could save the fiduciary standard. I don't usually write about politics, except when it has a direct impact on financial advice, and this appears to be one of those times.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
The Motley Fool January 30, 2007 Brian Lawler	Pfizer Fights a Generic Threat Pfizer attempts to fend off a generic threat in Canada for its top drug. It's a trial worth paying attention to for its shareholders, as Canada does represent one of the larger pharmaceutical markets in the world.
Registered Rep. May 29, 2007 Kristen French	Spitzer Forms Panel to Clean up NY Regulation Governor Eliot Spitzer is forming a panel to streamline regulations and make New York more competitive with London, but without sacrificing investor protection.
InternetNews May 28, 2010	FCC Has Broadband Regulations on its Agenda The Federal Communications plans to discuss Internet regulations and consumer protections at a meeting next month. How will the issue of net neutrality play out?
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
Insurance & Technology June 17, 2009 Anthony O'Donnell	Insurance Industry Reacts to President's Financial Service Regulation Reform Proposals President Obama's proposals include enhanced oversight of the insurance sector and the establishment of an Office of National Insurance.
The Motley Fool April 30, 2008 Brian Lawler	Pfizer Protects Profitable Patent The courts uphold a key patent on Pfizer's top drug.
Bank Director 4th Quarter 2009 William M. Aukamp	Some Thoughts on Regulatory Reform Before creating a new agency, Congress should be mindful of the already-heavy compliance burden born by banks.
Financial Advisor July 2005 Brian J. Jacobsen	The Danger Of Crossing Borders One of the clearest dangers to the financial services profession is when people cross borders; especially now, when brokers are behaving as advisors.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.